Citius Pharmaceuticals (NASDAQ:CTXR) Trading Up 11.1%
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s share price was up 11.1% on Tuesday . The company traded as high as $1.04 and last traded at $1.00, approximately 66,073 shares were traded during trading. A decline of 56% from the average daily volume of 149,961 shares. The stock had previously closed at $0.90.
A number of research analysts have recently weighed in on CTXR shares. Zacks Investment Research downgraded shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 9th. Dawson James started coverage on shares of Citius Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $7.00 target price for the company.
The stock’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.15. The stock has a market capitalization of $22.07 million, a P/E ratio of -0.85 and a beta of 0.68.
About Citius Pharmaceuticals (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.